p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.

Authors: Ruddell, A  Kelly-Spratt, KS  Furuya, M  Parghi, SS  Kemp, CJ 
Citation: Ruddell A, etal., Oncogene. 2008 May 15;27(22):3145-55. Epub 2007 Dec 3.
Pubmed: (View Article at PubMed) PMID:18059331
DOI: Full-text: DOI:10.1038/sj.onc.1210973

The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues. Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced squamous cell carcinomas, providing a model system to address mechanisms of metastasis. Here, we show that benign pre-metastatic papillomas from wild-type mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels. Lymph node lymphangiogenesis is greatly accelerated in papilloma-bearing p19/Arf- or p53-deficient mice, which coincides with the greater propensity of these tumors to progress to carcinomas and to metastasize. The extent of accumulation of B cells within the tumor-draining lymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential. Arf or p53 deficiency strongly accelerated lymph node immune cell accumulation, in a manner that was associated with the extent of lymph node lymphatic sinus growth. This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 8547790
Created: 2014-02-24
Species: All species
Last Modified: 2014-02-24
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.